Candida antigen

BIOLOGICAL5 trials

Sponsors

University of Arkansas, Assiut University, Zagazig University, Sohag University

Conditions

Common WartCondylomata AcuminataHPVWarts

Phase 1

Study With Candida Antigen for Treatment of Warts

CompletedNCT00569231

University of ArkansasHPV, Warts

Start: 2007-02-28End: 2010-01-31Updated: 2011-01-25

Phase 2

Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

CompletedNCT04399577

Zagazig UniversityWarts

Start: 2017-07-01End: 2019-09-03Updated: 2020-05-27

Phase 3

Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts

Assiut UniversityWarts

Start: 2018-03-01End: 2019-12-31Target: 70Updated: 2018-07-24

Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts

Assiut UniversityCondylomata Acuminata

Start: 2020-02-29End: 2021-12-31Target: 45Updated: 2019-03-12

Unknown Phase

Sclerotherapy and Candida Antigen in Treatment of Common Warts

Not yet recruitingNCT06749665

Sohag UniversityCommon Wart

Start: 2024-12-20End: 2025-12-01Target: 75Updated: 2024-12-27

Related Papers

Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts.

2022-12-263 citations

Complement component 3c and tumor necrosis factor-α systemic assessment after Candida antigen immunotherapy in cutaneous warts.

2020-06-273 citations

A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with <i>candida </i>skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Journal of Clinical Oncology2015-05-20